Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for August 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during August 2014.

For an indepth analysis of these deals, read 'Pharma deals during August 2014'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

InterMune/ Roche
Company acquisition
Pirfenidone for idiopathic pulmonary fibrosis (IPF) (approved EU, Canada)
8,300
MannKind/ Sanofi
Licence
Afrezza (human insulin) Rapid-Acting Inhaled Insulin (approved US)
925
Charleston Laboratories/ Daiichi Sankyo*
Collaboration (co-promotion rights)
Hydrocodone combination products, inc CL-108, for acute pain and reduction of Opioid-Induced Nausea and Vomiting (OINV) (phase III)
650
Gamida Cell/ Novartis
Investment, option to acquire
Stem cell therapies including NiCord (phase I/II)
635
Beijing Jialin Pharma/ Luye Pharma
Company acquisition (58%)
CV and cancer drug portfolio
600
TARIS Biomedical/ Allergan
Company acquisition
LiRIS for interstitial cystitis / bladder pain syndrome (IC/BPS) (phase II)
587.5
Santaris/ Roche (pRED)
Company acquisition
Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics
450
Sapiens Steering Brain Stimulation/ Medtronic
Company acquisition
Deep brain stimulation technologies for neurodegenerative diseases e.g. PD and essential tremor
200
Dream Pharma/ Alvogen
Company acquisition
Generics
187
Emergent BioSolutions/ Morphosys**
Licence, joint development & commercialisation
MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical)
183
Immune Design/ Sanofi
Licence
GLAAS discovery platform to develop therapeutics for a selected food allergy
168
Guizhou Taibang Biological Products/ China Biologic
Company acquisition (19.84% stake)
Plasma-based products
87.1+
Ziopharm Oncology/ Solasia Pharma
Amendment of 2011 licence/ collaboration
Darinaparsin (Zinapar or ZIO-101) and  related organoarsenic molecules
72.2
Millennium (Takeda)/ Infinity Pharma
Option to buy out future potential royalties
IPI-145 for treatment of blood cancers (phase III)
57.5
Rush University Medical Center/  DRI Capital
Acquisition of royalty rights
Ampyra (dalfampridine) extended release tablets (marketed)
42
Alpine Biosciences/ Oncothyreon
Company acquisition
Protocells, nanoparticle technology for targeted delivery of nucleic acids, proteins, peptides, small molecules (platform)
27
Valeo Pharma/ Valeant
Product portfolio acquisition
Dermatology brands and specialty products
25.3
ViaCyte/ Janssen R&D
Rights agreement
VC-01 based on pancreatic progenitor cells to treat type 1 diabetes (preclinical)
20
Hanmi Pharm/ Luye Pharma†Licence
Poziotinib, a pan-HER inhibitor for the treatment of cancer (phase II)
20

Abbott/ US Department of Defense
Collaboration
To develop portable blood tests to evaluate potential concussions or mild traumatic brain injuries (TBIs)
19.5

All deals are worldwide unless otherwise noted.
*    US
**  ww excluding US and Canada
†    China

The Deal Watch table is compiled by Medius Associates

11th September 2014

The Deal Watch table is compiled by Medius Associates

11th September 2014

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Infographics